Dow Up1.32% Nasdaq Up1.60%

Eventide Healthcare & Life Sciences N (ETNHX)

17.63 Up 0.54(3.16%) Oct 23

Profile as of Sep 29, 2014Get Profile for:
Eventide Healthcare & Life Sciences N
630-a Fitzwatertown Road2nd Floor
Map
Phone: 877-771-3836
Fund Overview 
Category:Health
Fund Family:Eventide Funds
Net Assets:109.07M
Year-to-Date Return:4.62%
Yield:0.00%
Morningstar Rating:N/A
Fund Inception Date:Dec 27, 2012
Morningstar Style Box 
Health
[View Category Definition]
View Top Health Funds
About the Morningstar Style Box
Management Information 
Finny Kuruvilla
Lead Manager since Dec 27, 2012
Finny Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT. Finny Kuruvilla has been a co-portfolio manager for the Eventide Gilead Fund since inception in July 2008 & manager of the Eventide Healthcare & Life Sciences Fund since inception in December 2012. Dr. Kuruvilla is also currently a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm.
Investment Information 
Min Initial Investment:1,000
Min Initial Investment, IRA:1,000
Min Initial Investment, AIP:100
Min Subsequent Investment:50
Min Subsequent Investment, IRA:50
Min Subsequent Investment, AIP:50
ETNHX can be purchased from 24 brokerages.

Fund Summary 
The investment seeks to provide long-term capital appreciation. Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It is non-diversified.

Fund Operations 
Last Dividend : N/A
Last Cap Gain : N/A
Annual Holdings Turnover : 33.00%
Average for Category:52.61%
Fees & Expenses 
ExpenseETNHXCategory Avg
Annual Report Expense Ratio (net):1.63%1.39%
Prospectus Net Expense Ratio:1.64%N/A
Prospectus Gross Expense Ratio:9.51%N/A
Max 12b1 Fee:0.20%N/A
Max Front End Sales Load:N/A5.28%
Max Deferred Sales Load: N/A2.37%
3 Yr Expense Projection*:2,044668
5 Yr Expense Projection*:3,7571,044
10 Yr Expense Projection*:7,4062,042
* Per $10,000 invested